Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Avorn

Showing results (31-40 of 436) with videos related to

Pageof 44
Sort By:
Annals of Internal Medicine|June 30, 2015
In Opposition to Liberty: We Need a "Sovereign" to Govern Drug ClaimsJerry Avorn
The New England Journal of Medicine|November 25, 2006
Dangerous deception--hiding the evidence of adverse drug effectsJerry Avorn
The New England Journal of Medicine|May 8, 2009
Debate about funding comparative-effectiveness researchJerry Avorn
Health Affairs (Project Hope)|October 7, 2003
Advertising and prescription drugs: promotion, education, and the public's healthJerry Avorn
Pharmacoeconomics|November 30, 2002
Balancing the cost and value of medications: the dilemma facing cliniciansJerry Avorn
Circulation|May 25, 2011
The relative cost-effectiveness of anticoagulants: obvious, except for the cost and the effectivenessJerry Avorn
Circulation|May 11, 2006
Evaluating drug effects in the post-Vioxx world: there must be a better wayJerry Avorn
The New England Journal of Medicine|March 31, 2006
Part "D" for "defective"--the Medicare drug-benefit chaosJerry Avorn
JAMA|December 10, 2017
Engaging With Patients on Health Policy Changes: An Urgent IssueJerry Avorn
JAMA|January 25, 2017
Academic Detailing: "Marketing" the Best Evidence to CliniciansJerry Avorn
Pageof 44

Showing results (31-40 of 436) with videos related to

Sort By:
Pageof 44
Annals of Internal Medicine|June 30, 2015
In Opposition to Liberty: We Need a "Sovereign" to Govern Drug ClaimsJerry Avorn
The New England Journal of Medicine|November 25, 2006
Dangerous deception--hiding the evidence of adverse drug effectsJerry Avorn
The New England Journal of Medicine|May 8, 2009
Debate about funding comparative-effectiveness researchJerry Avorn
Health Affairs (Project Hope)|October 7, 2003
Advertising and prescription drugs: promotion, education, and the public's healthJerry Avorn
Pharmacoeconomics|November 30, 2002
Balancing the cost and value of medications: the dilemma facing cliniciansJerry Avorn
Circulation|May 25, 2011
The relative cost-effectiveness of anticoagulants: obvious, except for the cost and the effectivenessJerry Avorn
Circulation|May 11, 2006
Evaluating drug effects in the post-Vioxx world: there must be a better wayJerry Avorn
The New England Journal of Medicine|March 31, 2006
Part "D" for "defective"--the Medicare drug-benefit chaosJerry Avorn
JAMA|December 10, 2017
Engaging With Patients on Health Policy Changes: An Urgent IssueJerry Avorn
JAMA|January 25, 2017
Academic Detailing: "Marketing" the Best Evidence to CliniciansJerry Avorn
Pageof 44